Here are seven updates on GI companies from the past week:
The FDA granted Custom Ultrasonics' System 83-plus Automated Endoscope Reprocessor approval to reprocess Olympus TJF-Q180V and Pentax ED-3490TK duodenoscopes.
Minneapolis-based Hennepin Healthcare partnered with Cantel Medical to install the nation's first Advantage Plus Pass-Thru Automated Endoscope Reprocessor.
Olympus Corp. donated approximately $3.2 million in medical equipment to the American Society for Gastrointestinal Endoscopy Foundation.
Synergy Pharmaceuticals presented data finding chronic idiopathic constipation and irritable bowel syndrome with constipation were both linked to depressed uroguanylin levels in patients.
Takeda announced results from its analysis of real-world data comparing the effectiveness of Entyvio to tumor necrosis factor-alpha antagonist therapy when treating inflammatory bowel disease patients.
Takeda Pharmaceutical Co. acquired 90.83 percent of TiGenix's voting rights through its previously announced takeover effort.
Exact Sciences and Rochester, Minn.-based Mayo Clinic researchers are developing a panel using blood-based DNA biomarkers to detect hepatocellular carcinoma.